key: cord-0888359-rcqjh8ox
authors: Sarkar, Amar; Harty, Siobhán; Moeller, Andrew H.; Klein, Sabra L.; Erdman, Susan E.; Friston, Karl J.; Carmody, Rachel N.
title: The Gut Microbiome as a Biomarker of Differential Susceptibility to SARS-CoV-2
date: 2021-10-06
journal: Trends Mol Med
DOI: 10.1016/j.molmed.2021.09.009
sha: 5ef3deeaf944392a5a18fb8b7d2b7891060fa050
doc_id: 888359
cord_uid: rcqjh8ox

COVID-19 continues to exact a devastating global toll. Ascertaining the factors underlying differential susceptibility and prognosis following viral exposure is critical to improving public health responses. We propose that gut microbes may contribute to variation in COVID-19 outcome. We synthesise evidence for gut microbial contributions to immunity and inflammation, and associations with demographic factors affecting disease severity. We suggest mechanisms potentially underlying microbially-mediated differential susceptibility to SARS-CoV-2, including gut microbiome-mediated priming of host inflammatory responses and regulation of endocrine signalling, with consequences for the cellular features that SARS-CoV-2 virions exploit. We argue that considering gut microbiome-mediated mechanisms may offer a lens for appreciating differential susceptibility to SARS-CoV-2, potentially contributing to clinical and epidemiological approaches to understanding and managing COVID-19.

antiviral response [17] . Similarly, antibiotic-induced ablation of gut microbial populations reduces the host's capacity to launch robust antiviral responses, and thus, influenza virus infection triggers more severe symptoms in antibiotic-treated mice compared to untreated controls [18] . These findings suggest that a healthy gut microbiome is necessary for appropriate antiviral defence. Gut microbial imbalances have been shown to affect acute inflammation well beyond the gut, including the lung. There is now extensive research elucidating the influence of gut microbes on pulmonary immunity through what is commonly referred to as the microbiome-gutlung axis [19] [20] [21] . Gut dysbiosis has been associated with infection by various respiratory viruses, including influenza A virus (IAV) and respiratory syncytial virus (RSV) [22, 23] .

Moreover, gut dysbiosis during influenza infection has been shown to contribute to pneumococcal superinfection in the lung [24] . The mechanisms underlying microbiome-gut-lung associations continue to be explored, but disturbances in the gut microbiome can increase the permeability of the intestinal barrier, permitting leakage and migration of gut bacteria to the lung, which may trigger local immune responses [25] . Microbial metabolites, such as short-chain fatty acids (SCFAs) derived from gut microbial fermentation of dietary fibre, have also been shown to modulate immunological reactivity in the lung [21, 26] and have even been detected in the lung compartment itself [27] . For instance, mice with high circulating SCFA levels were protected against allergic lung inflammation after exposure to dust mite extract [21] . This reduced reactivity was attributable to SCFA-induced alteration of bone marrow haematopoiesis, leading to the lungs possessing dendritic cells with an impaired capacity to activate effector T H 2 cells that potentiate pro-inflammatory responses. Overall, such results indicate roles for the gut microbiome in altering host responses to at least some respiratory infections.

Journal Pre-proof SARS-CoV-2 entry into susceptible cells is promoted by virus-cell fusion, which occurs when the SARS-CoV-2 spike protein binds to the cellular receptor angiotensin converting enzyme 2 (ACE2) and is cleaved by transmembrane protease serine 2 (TMPRSS2) and other host proteases, triggering conformational changes that enable membrane fusion [28, 29] . ACE2 and TMPRSS2 are abundant in alveolar tissue [28, 30] , but are also widely distributed across other host tissues, including the gut [31] [32] [33] [34] . Therefore, any effects of gut microbes on ACE2 and TMPRSS2 might be expected to affect the risk of SARS-CoV-2 infection.

COVID-19 has been observed to present with gastrointestinal symptoms and inflammation [35, 36] . Researchers have begun considering gut microbial contributions to COVID-19 outcomes [37] . In Table 1 , we summarise an emerging body of empirical research on the associations between SARS-CoV-2, COVID-19 outcomes, and microbial communities. Though we focus mainly on the gut microbiome in Table 1 , we also report data on host-associated microbiomes at other body sites as well. Collectively, these studies report differences in the microbial composition of COVID-19 patients compared to those of healthy controls or patients with non-COVID-19 pneumonia [38] [39] [40] [41] [42] [43] . Available studies are concurring that the gut microbial communities of COVID-19 patients exhibit lower taxonomic diversity [42] [43] [44] [45] and an increase in opportunistic pathogens [42] [43] [44] , although the extent to which these differences are attributable to concomitant antibiotic treatment in the hospital setting remains unclear. Moreover, the While the studies summarised in Table 1 are mostly correlational, some of the findings do appear to reconcile with the role that gut bacteria play in training and regulating the immune system and the particularly well-established link between gut microbes and the shaping of adaptive T and B cell responses, both locally and systemically [57] [58] [59] . Gnotobiotic studies have shown that both T cells and B cells are regulated by the microbiome. For instance, T-cell differentiation and proliferation depends on the presence of gut microbes [15] . Gut microbes have also been shown to play a crucial role in activating mucosal associated invariant T (MAIT) cells [60] , which have recently been found to be associated with differential susceptibility to SARS-CoV-2 infection and COVID-19 disease severity [61, 62] . We speculate that the microbiome, if it is indeed involved in differential susceptibility to SARS-CoV-2, may exert some of these effects via MAIT cells. Similarly, with respect to B cells, experiments in mice indicate that B cell differentiation is promoted indirectly by the gut microbiota through upregulation of interleukin production, specifically interleukin-1β (IL-1β) and interleukin-6 (IL-6) [63] .

Some of the dominant risk factors for severe COVID-19 outcomes are inflammationlinked metabolic and cardiovascular comorbidities such as diabetes and hypertension, and demographic characteristics such as older age (see Box 1), and male biological sex (see Box 2) [1, 2, 64] . Each of these characteristics is associated with variations in gut microbial composition and function.

Various gut microbiome-immune interactions modulate systemic and acute inflammation in the host. In many cases, the inflammatory landscape may in turn increase risk for virulent SARS-CoV-2 infection, culminating in cytokine storms characterised by very high J o u r n a l P r e -p r o o f Journal Pre-proof concentrations of circulating cytokines (e.g., IL-1β, IL-6, tumour necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), and macrophage inflammatory protein 1-α (MIP1α)], hyperinflammation (measured by biomarkers such as C-reactive protein), and eventual multiorgan failure and death [1] . Given relationships between gut microbes, host immunity, and host inflammatory status, it is conceivable that microbiome composition and function may confer risk for, or resilience against, the immune dysregulation and excessive inflammation characterising severe COVID-19 (see Figure 1 ). Importantly, inflammation also tends to increase with age in industrialized populations, and age is an important risk factor for COVID-19 (see Box 1) .

Murine research has confirmed a role for microbially-regulated host immunity and inflammation as a risk factor for cytokine storms [65, 66] . Cohousing specific pathogen-free laboratory mice with pathogen-harbouring pet store mice increased quantities of circulating monocytes and neutrophils expressing toll-like receptor 2 (TLR2) and TLR4 in the laboratory animals. These changes affected outcomes in a subsequent immune challenge involving Listeria monocytogenes, with cohoused laboratory mice exhibiting enhanced bacterial clearance but heightened sensitivity to cytokine storms and sepsis [65] . Similarly, exposure of laboratory mice to the microbial communities characterising wild-living mice led to elevated immune responses and increased probability of cytokine storms relative to unexposed laboratory controls [66] .

While these studies reported immune responses to novel pathogens, and therefore strong immune reactions are predicted a priori, these results do demonstrate that differences in baseline microbial composition among hosts was sufficient to affect the probability of cytokine storms. The vertebrate immune system has evolved to simultaneously defend against potential pathogens while developing tolerance for, and actively curating (to the extent possible), J o u r n a l P r e -p r o o f Journal Pre-proof beneficial and commensal microbes colonising the host [67, 68] . These contribute to the development and training of host immunity in early life, following which molecular dialogues between the microbiome and the host regulate immunity throughout the lifespan [15, 69, 70] .

Indeed, a recent study has demonstrated that human gut microbes are closely associated with circulating immune cells [71] . This study found strong associations between the genera Faecalibacterium, Ruminococcus, and Akkermansia and blood concentrations of neutrophils, lymphocytes, and monocytes. Moreover, gut microbes are implicated in the aetiopathogenesis of other diseases that are characterized by hyperinflammation, such as the autoimmune diseases rheumatoid arthritis and systemic lupus erythematosus. In these diseases, the gut microbiome can trigger symptoms in genetically susceptible individuals by producing orthologs of autoantigens, which can lead to microbiota-directed immune responses instead targeting host tissues, and through post-translational modification of autoantigens [72] . Impaired gut barrier function may also exacerbate inflammation in both autoimmune diseases [72] and COVID-19 [73] . While the gut microbiome in most healthy individuals facilitates immune homeostasis, compositional imbalances induced by host-driven or environmental factors can affect the integrity and selective permeability of the intestinal barrier with implications for inflammation [74] and cytokine storms [75] . Elevated intestinal barrier permeability can permit translocation of commensal and pathogenic microbes and their products into systemic circulation, which may in turn trigger heightened systemic inflammatory reactions, increased tissue damage, and ultimately chronic inflammation [76] . Unlike acute inflammatory responses, chronic inflammation is characterised by a dense infiltration of primary immune cells (e.g., lymphocytes, macrophages) in tissues. These cells produce proinflammatory cytokines, growth factors, and enzymes (e.g., nitric oxide synthase, matrix metalloproteinase), which lead to J o u r n a l P r e -p r o o f Journal Pre-proof sustained inflammation and persistent cycles of tissue damage and repair [77, 78] . Chronic lowgrade inflammation may increase the risk of harmful hyperinflammation in COVID-19 [1] , suggesting direct links between gut microbiota-mediated changes in gut barrier integrity and the risk of cytokine storms.

Microbial translocation into peripheral circulation, which occurs when gut barrier integrity is compromised, has been described as a characteristic feature of systemic inflammation among children suffering from SARS-CoV-2 complicated by multisystem inflammatory syndrome in children (MIS-C) [79] . Compared to children with acute COVID-19 and either seropositive children or controls, MIS-C patients displayed elevated serum lipopolysaccharide [79] . Similarly, children with acute COVID-19 showed higher serum lipopolysaccharide levels than seropositive individuals, and seropositive individuals showed higher serum lipopolysaccharide levels than controls, suggesting that lipopolysaccharides entering circulation due to enhanced gut permeability may be correlated with the severity of COVID-19 infection [79] . These correlations could potentially be driven in part by interactions between lipopolysaccharides and the SARS-CoV-2 spike protein. The SARS-CoV-2 spike protein has been shown to bind directly with lipopolysaccharide, affect the function of lipopolysaccharidebinding protein, and modulate the aggregation state of lipopolysaccharides, thereby boosting proinflammatory activity [80] . Combinations of lipopolysaccharide and the SARS-CoV-2 spike protein increased TLR4-mediated cytokine responses in human blood and peripheral blood mononuclear cells, an effect that was also confirmed in vivo using NF-κB reporter mice [80] . It is worth noting that cytokine storms typically result in intestinal damage [81, 82] , suggesting that impaired barrier function could potentially anchor a vicious cycle of escalating inflammation.

J o u r n a l P r e -p r o o f Journal Pre-proof Apart from altering probabilities of hyperinflammation, variation in baseline gut microbial profile and the resilience of the gut microbiota given SARS-CoV-2 infection may also modulate inflammation associated with metabolic diseases now known to increase the risk of severe COVID-19 outcomes, including diabetes mellitus [1] . For instance, several studies have found that antibiotic administration reduces inflammation and insulin resistance in high-fat dietfed mice or mice genetically susceptible to metabolic disease [83, 84] . Treatment with Akkermansia muciniphila, a microbe associated with increased gut barrier integrity in industrialized contexts, was sufficient to reverse high-fat diet-induced inflammation in insulinresistant mice [85] . Moreover, germ-free mice receiving microbial transfers from insulinresistant mice exhibited more inflammation than counterparts receiving microbial transfers from controls [84] . These results demonstrate a causal role for gut microbes in the generation of an inflammatory phenotype that could then serve as a risk factor in SARS-CoV-2 infection.

The associations between the microbiome and risk factors for COVID-19 such as host age and biological sex (see Boxes 1 and 2, respectively) can be investigated experimentally using animal models. Although mice are most commonly used in studies of both immune function and the microbiome, the existing SARS-CoV-2 virus now in circulation does not readily infect mice due to inefficient interactions with the mouse orthologue of ACE2 [86] . This limitation could be overcome through the use of ACE2 transgenic mice [87, 88] , mice transduced with adenoviruses encoding human ACE2 [89, 90] [44] . Infected unvaccinated mice showed reduced gut bacterial diversity relative to vaccinated mice exposed to SARS-CoV-2. Similar to changes previously observed in humans with COVID-19 relative to healthy controls (see Table 1 ), infected unvaccinated mice showed elevations in Odoribacter and Akkermansia muciniphila, as well as reductions in Lactobacillus reuteri and Bacteroides uniformis, relative to vaccinated animals.

Primate models which are susceptible to SARS-CoV-2 infection, such as macaques [92] , will doubtless also prove useful, given their closer phylogenetic relatedness and physiological similarity to humans. For instance, investigators have recently examined the microbial effects of SARS-CoV-2 infection in rhesus macaques and cynomolgus macaques [92] . SARS-CoV-2 infection triggered changes and ecological perturbations in the host gut microbiome that persisted over the course of the infection. The abundances of several bacterial taxa were found to be correlated with infection-related parameters, including nasal and rectal viral loads, C-reactive protein levels, and circulating levels of several proinflammatory cytokines. Many of the specific bacterial associations with systemic inflammatory markers mirrored those observed in humans (see Table 1 ), including positive correlations with Streptococcus and negative correlations with SCFA-producers such as the Ruminococcaceae. Correspondingly, the concentrations of several SCFAs were observed to decline in faeces during infection, although it remains unclear whether this drop was attributable to reduced bacterially-mediated SCFA production or increased SCFA utilization by host cells [92] .

Animal models can similarly be used to examine microbial associations with host differential susceptibility to SARS-CoV-2. For instance, consider the possibility that an aged microbiome may confer increased risk for severe infection. This possibility might be tested via J o u r n a l P r e -p r o o f experimental colonisation studies in gnotobiotic mice susceptible to SARS-CoV-2 or treated with the mouse-adapted SARS-CoV-2 MA virus [91] . Germ-free animals could be colonised with faecal microbial communities from young and old mice, or young and old humans, and then be exposed to the virus. If harbouring an aged microbiome is a risk factor for COVID-19, then we might expect faecal microbiota transplantation to trigger more severe symptoms in recipients of microbiotas from older individuals, relative to recipients with younger donors. In general, these types of studies demonstrate that animal models may be able to generate useful and finegrained information that can inform our understanding of the role of the microbiome in COVID-

It has become increasingly apparent that the enormous heterogeneity of exposure, susceptibility, virulence, transmission, and vaccination status play key roles in shaping the time course of the pandemic and variations between individuals, groups, communities, and nations [6, 7, [93] [94] [95] . Accounting for this heterogeneity suggests that the requisite levels of herd immunity may be lower than assumed under conventional models that often do not consider heterogeneity and differential susceptibility in detail. Differential susceptibility, though biologically realistic, is often difficult to incorporate into epidemiological models. To explain quantitative dissociations between the incidence of infection, time varying infection:fatality ratios, and fluctuations in seroprevalence, it is necessary to model populations as mixtures of individuals who are (i) more or less exposed to the virus-due to vaccination status, geospatial factors, population density, population-level behavioural factors such as mask-wearing, hand washing, self-isolation, time spent outdoors, and vaccination, and cultural factors such as the value placed on personal space, (ii) differentially capable of transmitting the virus-due to J o u r n a l P r e -p r o o f Journal Pre-proof differences in vaccination status or viral shedding [96] [97] [98] , and (iii) more or less susceptible to virulent infection-due to vaccination status, potential cross-reactive immunity with other βcoronaviruses, individual differences in the expression of ACE2 or TMPRSS2 [7, [99] [100] [101] , or other host factors that may constitute immunological dark matter.

In this context of differential susceptibility, the gut microbiome is a host factor that varies within and between individuals and, as described here, is broadly (and in some cases, causally) related to several major risk factors for severe COVID-19. Furthermore, variations in host genetics may also contribute to microbiome-associated susceptibility and protection, although these immunogenetic relationships await further study (see Box 3). Our suggestion is not that the microbiome is responsible for the majority of the variance associated with SARS-CoV-2

infection, but rather that the microbiome-being meaningfully correlated with several host factors relating to host immunity-may shed light on some of the immunological dark matter underlying differential susceptibility. Including information about the gut microbiome-and its impact on host immunity-into quantitative assessments of variations in risk and resilience, as summarised in Figure 2 , could contribute nuance to the development of public health interventions and messaging. For example, the identification of specific bacterial taxa whose relative abundances are associated with host susceptibility-combined with the application of rapid and low-cost methods for profiling gut microbiomes, such as taxon-specific 16S quantitative polymerase chain reaction (qPCR)-could enable pre-emptive population surveys or individual tests capable of estimating relative risk. These efforts could be furthered through large scale prospective studies to assess relationships between microbiome composition and infection outcomes. In addition to collecting microbiome data, prospective studies could leverage data pertaining to host inflammatory status, sex, age, and metabolic and cardiovascular health, each of J o u r n a l P r e -p r o o f Journal Pre-proof which is known to interact with the microbiome. Notably, because gut microbial interactions with inflammation and host factors such as age and sex may influence susceptibility and outcomes with respect to multiple viral pathogens, these efforts may yield insights relevant to SARS-CoV-2, other circulating viruses, and viruses that may become problematic in the future.

It is also generally thought that differential susceptibility and transmission reduce effective herd immunity thresholds [7, 102, 103] . If differences in the gut microbiome contribute to differential susceptibility, then consistent population-level differences in the gut microbiome (such as those seen between industrialised and non-industrialised populations and across lifestyle gradients [104] [105] [106] ) may meaningfully contribute to modelling population-level disease risks and herd immunity thresholds.

Of course, these situations are highly simplified. There is no single "resilient" microbiome, nor is there a strictly "neutral" microbiome. Furthermore, the sources of differential susceptibility (e.g., vaccination status, prior immunity, comorbidities, age, sex, microbial composition) do not confer their effects in isolation. Rather, they interact with one another to generate complex profiles of risk and resilience. Moreover, individual resilience and symptom severity are dynamic, as opposed to categorical, and are known to depend on the extent and duration of exposure to the virus (i.e., contact rates and mean periods of infectiousness).

Accordingly, susceptible individuals may avoid infection, and resistant or less-susceptible individuals may still contract the virus, although the latter would be expected to suffer fewer symptoms, recover more quickly, and be less infectious due to faster recovery, lower viral loads, or lower viral shedding rates.

J o u r n a l P r e -p r o o f Journal Pre-proof

We have highlighted how explicit considerations of the gut microbiome may elucidate aspects of COVID-19 risk and resilience. The microbiome is not presently systematically considered in COVID-19 research, despite its potential to affect infection response and supplement disease management. In this vein, there remain numerous important issues in need of investigation (see Outstanding Questions). However, there are also several areas where research can readily be conducted. For example, faecal samples can be acquired easily and non-invasively and used to assess interactions between the gut microbiome, COVID-19 risk factors, therapeutic interventions, and disease outcomes. Moreover, as discussed earlier, there are now several animal models being used to study COVID-19 [87] [88] [89] [90] 107] , and these too provide ready sources of microbial data, if researchers choose to collect faecal samples and profile the associated microbial communities through sequencing or targeted qPCR. Experiments with gnotobiotic animal models may prove especially useful, as these offer unique opportunities to isolate causal effects of the gut microbiome on host phenotypes. There are also a number of areas in which clinicians may benefit and to which they could contribute (see Clinician's Corner).

We note that many inconsistencies and contradictions exist across studies reporting interactions between the microbiome and human health [108] [109] [110] . A part of the difficulty arises from day-to-day gut microbial plasticity in response to variable environmental factors such as diet [111, 112] and the high degree of interindividual gut microbial dissimilarity across humans, which often necessitates longitudinal sampling or very large datasets to derive reliable patterns [113] . The COVID-19 pandemic provides precisely such an opportunity at a global scale.

Accordingly, we recommend routine collection and analysis of faecal samples alongside standard patient data. We also emphasise the need for prospective approaches characterising longitudinal J o u r n a l P r e -p r o o f Journal Pre-proof microbiome change as individuals progress from healthy to infected to recovered, as well as before and after vaccination. Overall, investigating the microbiome in the context of COVID-19 could deepen our understanding of the current pandemic, facilitate responses to future outbreaks, and advance our basic appreciation of the microbiome as a fundamental component-and regulator-of host immunity.

Greater age is an important risk factor for outcome severity in SARS-CoV-2 infection [2, [114] [115] [116] [117] [118] . Ageing also affects gut microbial structure and function, an association thought to be driven by senescence of the host immune system [119] [120] [121] . Covariation between host age, immunity, and microbial composition likely exert joint effects on inflammatory status and risk of disease. Although much human variation remains to be characterised, ageing appears to result in generally lower α-diversity coupled to increased relative abundance of pathobionts [121] [122] [123] [124] . A recent study investigated the causal role of gut microbes in regulating ageing-related inflammation and immunopathology by transplanting microbes from young or aged mice to young, germ-free recipients [125] . The germ-free recipients of microbial transplants from aged mice displayed a range of immunological changes relative to recipients with young donors, including elevated inflammation and increased gut barrier permeability as evidenced by increased translocation of microbial products (e.g., lipopolysaccharide) into systemic circulation [125] . Taken together, these general patterns suggest that the microbiome may contribute to elevated inflammation in elderly individuals, which may then act as a risk factor for more severe outcomes upon SARS-CoV-2 infection. Researchers have found sex differences in immune responses to SARS-CoV-2 [126] .

Biological males are at increased risk of both contracting SARS-CoV-2 infection and experiencing more virulent infection [127] . However, females appear more likely to display persistent, post-infection symptoms, including fatigue, anosmia, dyspnoea, and cognitive dysfunction [128] [129] [130] . These findings suggest female sex does not confer general protection, but rather that biological sex confers differential risks and protection in COVID-19. Furthermore, males and females respond differently to vaccines [131] , including against SARS-CoV-2. For instance, recent human findings suggest that vaccination triggers greater levels of immunoglobulin G (IgG) in females relative to males [132] .

Potential Mechanisms: The X chromosome is enriched in genes regulating host immunity [133] , and this chromosomal difference may be one of the causes underlying sex differences in host responses to SARS-CoV-2 [127] . Another mechanism underlying observed sex differences in COVID-19 outcomes may be the action of sex steroids. Sex steroids regulate the availability of both ACE2 and TMPRSS2, the cell-surface molecular features exploited by SARS-CoV-2 virions. For instance, it appears that androgens (predominant in males) upregulate both ACE2 and TMPRSS2 [134] [135] [136] [137] [138] , whereas oestrogens (predominant in females) appear to downregulate these molecular targets [139] [140] [141] . Notably, castration of mice or androgen deprivation in mouse and human cells reduced ACE2 and TMPRSS2 expression and protein levels, and androgen deprivation or anti-androgen treatment diminished entry of SARS-CoV-2 into lung cells [134] .

Correspondingly, human males undergoing androgen-deprivation treatment for prostate cancer experience less severe COVID-19 outcomes [135] , and blocking androgenic signalling is associated with reduced ACE2 levels and reduced risk of severe COVID-19 outcomes [136] . Moreover, sex hormones also regulate host inflammatory tone. Intriguingly, androgens have been reported to exert mostly anti-inflammatory effects [142] , despite their association with more severe COVID-19 outcomes. By contrast, oestrogens may exert either anti-inflammatory or pro-inflammatory effects, depending on the receptor [142] . In general, hormone levels vary across individuals of a given biological sex. This variation may influence the extent to which host inflammation is a risk factor, and may dampen associations between biological sex and COVID-19 outcomes, potentially explaining some variation in susceptibility among individuals of a given biological sex.

There is some evidence of sex differences in the mammalian gut microbiome [119] [120] [121] [143] [144] [145] [146] [147] [148] [149] . Crucially, the gut microbiome regulates the bioavailability of sex steroids [108, 145, 150] . For example, germ-free male mice show markedly lower testosterone concentrations, suggesting that the presence of microbial populations increases the quantity of testosterone in males [145] . Moreover, transferring gut microbes from adult males into preadolescent female mice increases testosterone concentrations in recipients [145] , adding inductive support to the causal role of the microbiome in testosterone regulation.

Gut microbes also regulate oestradiol bioavailability. For instance, numerous gut bacterial taxa secrete β-glucuronidase, which deconjugates oestradiol that has undergone conjugation by the liver and excretion into the gut lumen via bile. Deconjugation returns luminal oestradiol to its active form and enables re-entry into host circulation, thus increasing the host's bioavailable oestrogen [151] [152] [153] . Correspondingly, antibiotic administration increased quantities of conjugated oestrogens excreted in host faeces in both males and females [154] [155] [156] . Moreover, gut microbes can increase oestrogen activity via biotransformation of diet-derived phytoestrogens [157, 158] . Overall, therefore, gut microbes play important roles in sex steroid J o u r n a l P r e -p r o o f Journal Pre-proof bioavailability, and sex steroids in turn regulate inflammation and the availability of the cellsurface features exploited by SARS-CoV-2.

What is the role of host genetics in the microbiome-COVID-19 association? Differential susceptibility to SARS-CoV-2 is also a matter of immunogenetic variation, which has indeed been associated with variation in COVID-19 susceptibility and outcomes [159] [160] [161] . Host genes also contribute to variation in gut microbial composition, as evidenced by twin studies [162] [163] [164] [165] , genome-wide association studies in humans [166] [167] [168] [169] [170] , as well as largescale, long-term studies in non-human primates [171] . Although global genetic factors explain less variation than environmental factors [172] , specific gene variants have been shown to meaningfully affect gut microbial community composition, including LCT, VDR, NOD2, ABO and FUT2 [162, 166, 170, 173] . Researchers have also been interested in the interactions between host genes and the gut microbiome in the context of disease [162] . Although associations are generally small and many mechanisms remain unclear, genome-microbiome-disease interactions raise the possibility that, in addition to modulating COVID-19 resistance and susceptibility through the immune system, host genes may also affect disease resistance and susceptibility through effects on the gut microbiome.

A further interesting immunogenetic connection of potential relevance to COVID-19 outcomes is the blood group of the host. Importantly, natural blood group antibodies can recognise members of the gut microbiome [174] and also shape gut microbial composition and ecology [173, 175] . These associations have been studied in the context of inflammatory conditions such as inflammatory bowel disease [173] , but have not yet been extended to COVID-J o u r n a l P r e -p r o o f Journal Pre-proof 19 . This connection is particularly relevant because blood groups have also been associated with COVID-19 outcomes, with O and Rh-blood groups appearing to confer protective effects in the context of SARS-CoV-2 infection [176] . These findings provide a further potential link between the gut microbiota and COVID-19 outcomes.  During treatment, clinicians could seek to obtain information about ongoing and previous antibiotic use of COVID-19 patients. This will enable inferences about the patient's baseline level of gut dysbiosis, and will help to contextualise the results of any microbial profiling studies carried out.

 A recent meta-analysis suggests that physicians prescribe antibiotics to COVID-19 patients at rates substantially higher than estimated rates of bacterial co-infection in COVID-19 cases, J o u r n a l P r e -p r o o f Journal Pre-proof suggesting some degree of antibiotic overuse [177] . If antibiotics are used to treat bacterial infections associated with COVID-19, clinicians should consider whether it may be appropriate to replenish beneficial and commensal microbes via the use of prebiotics or probiotics. In addition, if the circumstances permit, it may be feasible to use narrow-spectrum antibiotics that could help to preserve broader gut microbial integrity.

 During treatment, clinicians could consider assessing circulating markers of compromised gut barrier function, such as serum lipopolysaccharide. This will help researchers understand the extent to which gut permeability is increased in COVID-19 and perhaps whether gut permeability predicts disease severity.

 Given that many therapeutic drugs are chemically modified by the gut microbiome and that such activities can profoundly alter their effectiveness [178, 179] , it would be valuable to assess the relationships between the gut microbiome and patient outcomes in the context of current COVID-19 treatments. Advancing such knowledge could ultimately enable clinicians to one day use the microbiome as a diagnostic tool to contribute to decisions about the best course of treatment. COVID-19 was associated with significantly higher relative abundance of opportunistic pathogens, (including Clostridium hathewayi, Actinomyces viscosus, and Bacteroides nordii) and a lower relative abundance of commensal symbionts (including Eubacterium, Faecalibacterium prausnitzii, Roseburia, and Lachnospiraceae). Changes in the abundance of species from the Bacteroides genus over the course of hospitalisation were inversely correlated with SARS-CoV-2 load in faecal samples. Several of these bacteria (e.g. Bacteroides massiliensis, Bacteroides dorei, Bacteroides thetaiotaomicron) have been linked with downregulation of ACE2 in the murine gut, and were inversely correlated with SARS-CoV-2 load in human faecal samples. [43] J o u r n a l P r e -p r o o f 

COVID-19 in people with diabetes: understanding the reasons for worse outcomes

Factors associated with COVID-19-related death using OpenSAFELY

Dynamic causal modelling

Superspreading and the effect of individual variation on disease emergence

Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China

Dark matter', second waves and epidemiological modelling

Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold

Dynamic causal modelling of immune heterogeneity

The impact of host resistance on cumulative mortality and the threshold of herd immunity for SARS-CoV-2

Endogenous Enterobacteriaceae underlie variation in susceptibility to Salmonella infection

Composition of the gut microbiota modulates the severity of malaria

The hygiene hypothesis, the COVID pandemic, and consequences for the human microbiome

Interactions between the microbiota and the immune system

The gut microbiota shapes intestinal immune responses during health and disease

Gut immune maturation depends on colonization with a hostspecific microbiota

The human microbiome and COVID-19: A systematic review

Metatranscriptomic characterization of Coronavirus Disease 2019 identified a host transcriptional classifier associated with immune signaling

The active lung microbiota landscape of COVID-19 patients

The lung tissue microbiota features of 20 deceased patients with COVID-19

Genomic diversity of Severe Acute Respiratory Syndrome-Coronavirus 2 in patients with Coronavirus Disease

Alterations of the gut microbiota in patients with Coronavirus Disease 2019 or H1N1 influenza

Alterations in gut microbiota of patients with COVID-19 during time of hospitalization

Integrated gut virome and bacteriome dynamics in COVID-19 patients

Six-month follow-up of gut microbiota richness in patients with COVID-19

Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19

Gut microbiota, inflammation, and molecular signatures of host response to infection

Butyrate-producing bacteria supplemented in vitro to Crohn's disease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier integrity

Bacterial modification of the host glycosaminoglycan heparan sulfate modulates SARS-CoV-2 infectivity

Heparan sulfate in the developing, healthy, and injured lung

Adaptive immunity to SARS-CoV-2 and COVID-19

Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

Long-term persistence of IgG antibodies in SARS-CoV infected healthcare workers

T cell responses to whole SARS coronavirus in humans

Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals

SARS-CoV-2-indigenous microbiota nexus: does gut microbiota contribute to inflammation and disease severity in COVID-19? Front

The microbiome and immune memory formation

Functional role of mucosal-associated invariant T cells in HIV infection

MAIT cells are imprinted by the microbiota in early life and promote tissue repair

Phenotypical and functional alteration of unconventional T cells in severe COVID-19 patients

MAIT cell activation and dynamics associated with COVID-19 disease severity

Regulatory B cells are induced by gut microbiota-driven interleukin-1β and interleukin-6 production

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Microbial exposure enhances immunity to pathogens recognized by TLR2 but increases susceptibility to cytokine storm through TLR4 sensitization

Laboratory mice born to wild mice have natural microbiota and model human immune responses

The evolution of the host microbiome as an ecosystem on a leash

Care for the community

The maternal microbiota drives early postnatal innate immune development

The microbiome and innate immunity

The gut microbiota is associated with immune cell dynamics in humans

The microbiome in systemic autoimmune disease: mechanistic insights from recent studies

Do an altered gut microbiota and an associated leaky gut affect COVID -19 severity? mBio

Microbial regulation of organismal energy homeostasis

Evidence that lipopolisaccharide may contribute to the cytokine storm and cellular activation in patients with visceral leishmaniasis

Microbiota and diabetes: an evolving relationship

Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis

Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment

Systemic inflammation and microbial translocation are characteristic features of SARS-CoV-2-related multisystem inflammatory syndrome in children

SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity

Could perturbation of gut microbiota possibly exacerbate the severity of COVID-19 via cytokine storm?

Pathology and pathogenesis of severe acute respiratory syndrome

Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice

Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5

Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies

Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota

How vaccination and contact isolation might interact to suppress transmission of Covid-19: a DCM study

Dynamic causal modelling of COVID-19

A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

Virological assessment of hospitalized patients with COVID-2019

Nasal gene expression of angiotensin-converting enzyme 2 in children and adults

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

The role of innate lymphoid cells in response to microbes at mucosal surfaces

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Vitamin D levels and COVID-19 susceptibility: is there any correlation?

Gut microbiome transition across a lifestyle gradient in Himalaya

Seasonal cycling in the gut microbiome of the Hadza huntergatherers of Tanzania

US immigration westernizes the human gut microbiome

Animal models for COVID-19

The role of the microbiome in the neurobiology of social behaviour

Microbiology: microbiome science needs a healthy dose of scepticism

Establishing or exaggerating causality for the gut microbiome: lessons from human microbiota-associated rodents

Cooking shapes the structure and function of the gut microbiome

Diet rapidly and reproducibly alters the human gut microbiome

A framework for microbiome science in public health

Age-dependent effects in the transmission and control of COVID-19 epidemics

Covid-19: risk factors for severe disease and death

Epidemiology and transmission dynamics of COVID-19 in two Indian states

Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Sex differences in the gut microbiome-brain axis across the lifespan

Our gut microbiome: the evolving inner self

Human gut microbiome viewed across age and geography

Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians

Composition, variability, and temporal stability of the intestinal microbiota of the elderly

Combined PCR-DGGE fingerprinting and quantitative-PCR indicates shifts in fecal population sizes and diversity of Bacteroides, bifidobacteria and Clostridium cluster IV in institutionalized elderly

Aged gut microbiota contributes to systemical inflammaging after transfer to germ-free mice

Sex differences in immune responses that underlie COVID-19 disease outcomes

Considering how biological sex impacts immune responses and COVID-19 outcomes

Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients

Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients

Attributes and predictors of long COVID

Sex and gender differences in the outcomes of vaccination over the life course

COVID-19 mRNA vaccination generates greater immunoglobulin G levels in women compared to men

Sex differences in immune responses

Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19

Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532)

Androgen signaling regulates SARS-CoV-2 receptor levels and is associated with severe COVID-19 symptoms in men

TMPRSS2 and COVID-19: serendipity or opportunity for intervention? Cancer Discov

Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2

Protective regulation of the ACE2/ACE gene expression by estrogen in human atrial tissue from elderly men

Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17β-oestradiol-dependent and sex chromosome-independent

Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells

Glucocorticoids, sex hormones, and immunity

Host gender and androgen levels regulate gut bacterial taxa in pigs leading to sex-biased serum metabolite profiles

Estrogen-mediated gut microbiome alterations influence sexual dimorphism in metabolic syndrome in mice

Sex differences in the gut microbiome drive hormonedependent regulation of autoimmunity

Sex differences and hormonal effects on gut microbiota composition in mice

A reference gene catalogue of the pig gut microbiome

Gender bias in autoimmunity is influenced by microbiota

Sex-and age-related trajectories of the adult human gut microbiota shared across populations of different ethnicities

You've got male: sex and the microbiota-gut-brain axis across the lifespan

Distribution of β-glucosidase and β-glucuronidase activity and of βglucuronidase gene gus in human colonic bacteria: β-glycosidase activity in human gut bacteria

The intestinal microbiome and estrogen receptor-positive female breast cancer

Microbiome and malignancy

Effect of ampicillin administration on the excretion of twelve oestrogens in pregnancy urine

Effect of oxytetracycline administration on intestinal metabolism of oestrogens and on plasma sex hormones in healthy men

Excretion of progesterone metabolites and estriol in faeces from pregnant women during ampicillin administration

Genetic basis for the cooperative bioactivation of plant lignans by Eggerthella lenta and other human gut bacteria

Lignan transformation by gut bacteria lowers tumor burden in a gnotobiotic rat model of breast cancer

The Severe Covid-19 GWAS Group (2020) Genomewide association study of severe Covid-19 with respiratory failure

COVID-19 Host Genetics Initiative (2021) Mapping the human genetic architecture of COVID-19

The major genetic risk factor for severe COVID-19 is inherited from Neanderthals

Human genetic variation and the gut microbiome in disease

Genetic determinants of the gut microbiome in UK twins

Human genetics shape the gut microbiome

Shotgun metagenomics of 250 adult twins reveals genetic and environmental impacts on the gut microbiome

Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota

Association of host genome with intestinal microbial composition in a large healthy cohort

The effect of host genetics on the gut microbiome

Host genetic variation impacts microbiome composition across human body sites

Host genetic variation and its microbiome interactions within the Human Microbiome Project

Gut microbiome heritability is nearly universal but environmentally contingent

Environment dominates over host genetics in shaping human gut microbiota

Genome-wide association study in 8,956 German individuals identifies influence of ABO histo-blood groups on gut microbiome

Innate immune lectins kill bacteria expressing blood group antigen

Blood type and the microbiome-untangling a complex relationship with lessons from pathogens

Association between ABO and Rh blood groups and SARS-CoV-2 infection or severe COVID-19 illness: a population-based cohort study

Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis

Mapping human microbiome drug metabolism by gut bacteria and their genes

The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism

Progressive worsening of the respiratory and gut microbiome in children during the first two months of COVID-19

COVID-19 severity and complications associated with low diversity, dysbiosis and predictive metagenome features of the oropharyngeal microbiome

Dynamics of the upper respiratory tract microbiota and its association with mortality in COVID-19

The commensal microbiota and viral infection: a comprehensive review

We thank Cary Allen-Blevins, Katia Chadaideh, Benjamin Ho, Laura Schell, and Emily Venable